Skip to main content
Premium Trial:

Request an Annual Quote

Pharmagene, WITA Proteomics Collaborate on Drug Discovery

NEW YORK, March 13 - Pharmagene and WITA Proteomics have agreed to work together to provide a full service drug discovery and validation service for pharmaceutical and biotechnology customers, the companies said Tuesday.

Pharmagene, a five year-old biotechnology company based in Royston, UK, specializes in human tissue analysis and pharmaceutical development. Together with WITA Proteomics, based in Teltow, Germany, the companies will try to leverage their functional pharmacology and proteomics capabilities to develop drug targets, said Andreas Koepke, CEO of WITA Proteomics.

"The driver behind this is to provide a full-fledged service for drug development--from tissue to proteomics and genomics--to acquire new customers," said Koepke of the non-exclusive arrangement.

Terms of the deal were not disclosed.

WITA Proteomics has about 13 employees and uses 2-D Electrophoresis and mass spectrometric techniques to isolate and identify proteins, Koepke said. Current customers include Janssen Research Foundation, a division of Johnson and Johnson, and BRAHMS, a diagnostics company based in Berlin. The company has raised 4.4 million euros ($4.1 million) since being spun off from WITA, a biotechnology company, last year.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.